Fibrocell Science announces plans to price public sale of common stock

Bookrunner Barclays and co-managers Wedbush PacGrow and Griffin assist

By Devika Patel

Knoxville, Tenn., Sept. 25 - Fibrocell Science, Inc. said it plans to price a public offering of common stock. The deal will have a 30-day 15% greenshoe option.

Barclays is the sole bookrunner. Wedbush PacGrow Life Sciences and Griffin Securities are the co-managers.

Proceeds will be used for Phase III clinical trials for additional azficel-T indications, to progress collaboration programs with Intrexon Corp. and for working capital and general corporate and administrative expenses.

Fibrocell is a biotechnology company based in Exton, Pa.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.